March 5 (Reuters) - Jazz Pharmaceuticals JAZZ.O will acquire biotech firm Chimerix CMRX.O for about $935 million to gain access to its experimental drug to treat a rare brain tumor, the companies said on Wednesday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.